These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24566189)

  • 1. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide.
    García-Quintanilla M; Pulido MR; Moreno-Martínez P; Martín-Peña R; López-Rojas R; Pachón J; McConnell MJ
    Antimicrob Agents Chemother; 2014 May; 58(5):2972-5. PubMed ID: 24566189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.
    García-Quintanilla M; Carretero-Ledesma M; Moreno-Martínez P; Martín-Peña R; Pachón J; McConnell MJ
    Int J Antimicrob Agents; 2015 Dec; 46(6):696-702. PubMed ID: 26391380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii.
    Carretero-Ledesma M; García-Quintanilla M; Martín-Peña R; Pulido MR; Pachón J; McConnell MJ
    Virulence; 2018 Dec; 9(1):930-942. PubMed ID: 29638177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.
    Moffatt JH; Harper M; Harrison P; Hale JD; Vinogradov E; Seemann T; Henry R; Crane B; St Michael F; Cox AD; Adler B; Nation RL; Li J; Boyce JD
    Antimicrob Agents Chemother; 2010 Dec; 54(12):4971-7. PubMed ID: 20855724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.
    Kamoshida G; Yamada N; Nakamura T; Yamaguchi D; Kai D; Yamashita M; Hayashi C; Kanda N; Sakaguchi M; Morimoto H; Sawada T; Okada T; Kaya Y; Takemoto N; Yahiro K
    Microbiol Spectr; 2022 Oct; 10(5):e0192822. PubMed ID: 36173297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii.
    Napier BA; Burd EM; Satola SW; Cagle SM; Ray SM; McGann P; Pohl J; Lesho EP; Weiss DS
    mBio; 2013 May; 4(3):e00021-13. PubMed ID: 23695834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii.
    Moffatt JH; Harper M; Adler B; Nation RL; Li J; Boyce JD
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3022-4. PubMed ID: 21402838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.
    Martínez-Guitián M; Vázquez-Ucha JC; Odingo J; Parish T; Poza M; Waite RD; Bou G; Wareham DW; Beceiro A
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4375-9. PubMed ID: 27139471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.
    Saugar JM; Rodríguez-Hernández MJ; de la Torre BG; Pachón-Ibañez ME; Fernández-Reyes M; Andreu D; Pachón J; Rivas L
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1251-6. PubMed ID: 16569836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septal Class A Penicillin-Binding Protein Activity and ld-Transpeptidases Mediate Selection of Colistin-Resistant Lipooligosaccharide-Deficient Acinetobacter baumannii.
    Kang KN; Kazi MI; Biboy J; Gray J; Bovermann H; Ausman J; Boutte CC; Vollmer W; Boll JM
    mBio; 2021 Jan; 12(1):. PubMed ID: 33402533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii.
    Pelletier MR; Casella LG; Jones JW; Adams MD; Zurawski DV; Hazlett KR; Doi Y; Ernst RK
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4831-40. PubMed ID: 23877686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
    Cai Y; Li R; Liang B; Bai N; Liu Y; Wang R
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3998-9. PubMed ID: 20585134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii.
    Lee JY; Hong YK; Ko KS
    Diagn Microbiol Infect Dis; 2020 Apr; 96(4):114965. PubMed ID: 32019695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment.
    Soon RL; Nation RL; Cockram S; Moffatt JH; Harper M; Adler B; Boyce JD; Larson I; Li J
    J Antimicrob Chemother; 2011 Jan; 66(1):126-33. PubMed ID: 21081544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy.
    Soon RL; Nation RL; Harper M; Adler B; Boyce JD; Tan CH; Li J; Larson I
    Int J Antimicrob Agents; 2011 Dec; 38(6):493-501. PubMed ID: 21925844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient Acinetobacter baumannii.
    Boll JM; Crofts AA; Peters K; Cattoir V; Vollmer W; Davies BW; Trent MS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6228-E6237. PubMed ID: 27681618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
    Li J; Nation RL; Owen RJ; Wong S; Spelman D; Franklin C
    Clin Infect Dis; 2007 Sep; 45(5):594-8. PubMed ID: 17682994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
    Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii.
    Plachouras D; Giamarellos-Bourboulis EJ; Kentepozidis N; Baziaka F; Karagianni V; Giamarellou H
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):419-22. PubMed ID: 17188449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of large amounts of lipopolysaccharides from Pseudomonas aeruginosa cells reduces their susceptibility to colistin.
    Yokota SI; Hakamada H; Yamamoto S; Sato T; Shiraishi T; Shinagawa M; Takahashi S
    Int J Antimicrob Agents; 2018 Jun; 51(6):888-896. PubMed ID: 29432867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.